General principles of medical therapy of inflammatory bowel disease

被引:30
作者
Friedman, S [1 ]
机构
[1] Harvard Univ, Sch Med, Brigham & Womens Hosp, Gastroenterol Div ASBII,Dept Med, Boston, MA 02115 USA
关键词
D O I
10.1016/j.gtc.2004.02.003
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Ulcerative colitis (UC) and Crohn's disease (CD) are chronic gastrointestinal diseases that affect patients in the prime of their lives. Most patients need to take daily medications from diagnosis until death. Because inflammatory bowel disease (IBD) patients generally have a normal lifespan, chronic medical therapy for IBD must be tolerable, simple to adhere to, and have as few side effects as possible. Different patients require different types of medical therapy and treatment goals of physicians should reflect those of their patients. This article discusses the impact of IBD on quality of life and stresses the importance of appropriate and individualized medical therapy. To help clinicians determine the efficacy of particular 11313 medications, this article offers a brief, practical interpretation of clinical, endoscopic, and quality-of-life end points used in clinical trials. Finally, it provides a summary of the current accepted medical therapies for UC and CD and recommendations for using these medications in clinical practice.
引用
收藏
页码:191 / +
页数:19
相关论文
共 97 条
  • [1] CONTINUOUSLY INFUSED CYCLOSPORINE AT LOW-DOSE IS SUFFICIENT TO AVOID EMERGENCY COLECTOMY IN ACUTE ATTACKS OF ULCERATIVE-COLITIS WITHOUT THE NEED FOR HIGH-DOSE STEROIDS
    ACTIS, GC
    OTTOBRELLI, A
    PERA, A
    BARLETTI, C
    PONTI, V
    PINNAPINTOR, M
    VERME, G
    [J]. JOURNAL OF CLINICAL GASTROENTEROLOGY, 1993, 17 (01) : 10 - 13
  • [2] Efficacy and efficiency of oral microemulsion cyclosporin versus intravenous and soft gelatin capsule cyclosporin in the treatment of severe steroid-refractory ulcerative colitis: An open-label retrospective trial
    Actis, GC
    Aimo, G
    Priolo, G
    Moscato, D
    Rizzetto, M
    Pagni, R
    [J]. INFLAMMATORY BOWEL DISEASES, 1998, 4 (04) : 276 - 279
  • [3] Actis GC, 2000, AM J GASTROENTEROL, V95, P830
  • [4] Alfadhli AA, 2003, COCHRANE DB SYST REV
  • [5] Azathioprine in steroid-resistant and steroid-dependent ulcerative colitis
    Ardizzone, S
    Molteni, F
    Imbesi, V
    Bollani, S
    Porro, GB
    [J]. JOURNAL OF CLINICAL GASTROENTEROLOGY, 1997, 25 (01) : 330 - 333
  • [6] Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease
    Baert, F
    Noman, M
    Vermeire, S
    Van Assche, G
    D'Haens, G
    Carbonez, A
    Rutgeerts, P
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (07) : 601 - 608
  • [7] Inflammatory bowel disease - Medical therapy of specific clinical presentations
    Banerjee, S
    Peppercorn, MA
    [J]. GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 2002, 31 (01) : 185 - +
  • [8] BARON JH, 1962, BRIT MED J, P441
  • [9] BEST WR, 1979, GASTROENTEROLOGY, V77, P843
  • [10] The impact of inflammatory bowel disease on labor force participation:: Results of a population sampled case-control study
    Boonen, A
    Dagnelie, PC
    Feleus, A
    Hesselink, MA
    Muris, JW
    Stockbrügger, RW
    Russel, MG
    [J]. INFLAMMATORY BOWEL DISEASES, 2002, 8 (06) : 382 - 389